Image - 12 March 2025

Pär Gellerfors and Lars Lannfelt

License:: Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
By:: BioArctic
Copyright:: BioArctic
File format:: .jpg
Size:: 4480 x 6720, 21 MB

Download

Topics

Contacts

Elin Bäckström

Press contact Press Officer Research Education elin.backstrom@uu.se +46-70-425 09 83

Linda Koffmar

Press contact Press Officer linda.koffmar@uu.se +46 (0)18-471 19 59

Sandra Gunnarsson

Press contact Press Officer sandra.gunnarsson@uu.se +4673 469 75 92

Trio behind Alzheimer’s drug receives Uppsala University Innovation and Entrepreneurship Award

The drug that slows down Alzheimer’s disease is already being used by more than 20,000 patients in 10 different countries – and could soon be available in Europe too. The success story is down to the two founders of BioArctic Lars Lannfelt and Pär Gellerfors and the company’s CEO Gunilla Osswald. Their achievement is now recognised by the Uppsala University Innovation and Entrepreneurship Award.

Uppsala University - quality, knowledge, and creativity since 1477

Founded in 1477, Uppsala University is the oldest university in Sweden. With more than 50,000 students and 7,500 employees in Uppsala and Visby, we are a broad university with research in social sciences, humanities, technology, natural sciences, medicine and pharmacology. Our mission is to conduct education and research of the highest quality and relevance to society on a long-term basis. Uppsala University is regularly ranked among the world’s top universities.